McCall Shannon J, Tuttle-Newhall Janet E, Howell David N, Fields Timothy A
Department of Pathology, Duke University Medical Center, Durham, NC, USA.
Transplantation. 2003 Jun 15;75(11):1847-52. doi: 10.1097/01.TP.0000063126.88887.68.
With a continuing demand for donor kidneys for organ transplantation, it is important to understand the significance of pathologic findings in the donor organ before transplantation. Microvascular thrombosis is sometimes encountered in association with disseminated intravascular coagulation in the donor, and it is unclear whether this finding may affect immediate allograft function and long-term graft survival. To further elucidate this question, we examined our experience with microvascular thrombosis in donor biopsies in the kidney transplant program at our institution.
Donor kidney biopsies showing microvascular thrombosis were identified from consecutive donor biopsies in the Duke University Medical Center transplant file database between January 1, 1995 and December 31, 2000. These biopsies and all other kidney biopsies and specimens from the recipients of these kidneys thus identified were reviewed. Sections were stained using a variety of methods, including hematoxylin-eosin, periodic acid-Schiff, methenamine silver, and Masson trichrome methods. Clinical records of the transplant recipients of these kidneys were also reviewed to assess allograft performance and survival.
From 230 consecutive donor kidney biopsies, we identified eight cases exhibiting donor-microvascular thrombosis. Mean follow-up times were 27.5 months for the thrombi group and 35 months for the non-thrombi group. Recipients of grafts with donor thrombi were more likely to exhibit delayed graft function, but graft function at 1 and 2 years and graft survival were similar between the two groups. Subsequent posttransplantation biopsies in five of eight cases showed no evidence of residual thrombosis.
These data suggest that the presence of donor microvascular thrombosis does not portend poor outcome in renal transplantation.
随着对器官移植供肾需求的持续增加,了解移植前供肾病理结果的意义非常重要。供体中有时会出现与弥散性血管内凝血相关的微血管血栓形成,目前尚不清楚这一发现是否会影响移植肾的即刻功能和长期存活。为了进一步阐明这个问题,我们研究了本机构肾移植项目中供体活检发现微血管血栓的情况。
从1995年1月1日至2000年12月31日杜克大学医学中心移植文件数据库中连续的供体肾活检中,找出显示微血管血栓形成的活检样本。对这些活检样本以及由此确定的这些肾脏受者的所有其他肾活检样本和标本进行回顾。切片采用多种方法染色,包括苏木精-伊红染色、过碘酸-希夫染色、亚甲胺银染色和马松三色染色法。还回顾了这些肾脏移植受者的临床记录,以评估移植肾的功能和存活情况。
在连续230例供体肾活检中,我们发现8例存在供体微血管血栓形成。血栓组的平均随访时间为27.5个月,非血栓组为35个月。有供体血栓的移植肾受者更易出现移植肾功能延迟恢复,但两组在1年和2年时的移植肾功能及移植肾存活率相似。8例中有5例移植后的后续活检未发现残留血栓的证据。
这些数据表明,供体微血管血栓形成的存在并不预示肾移植预后不良。